Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>35 years~* Exudative, active PCV in 1 eye.~* PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography.~Exclusion Criteria:~* Age \<35 years~* Prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ranibizumab 0.5 mg/ 0.05 cc (Type: EXPERIMENTAL): Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
- Ranibizumab 0.3 mg/ 0.05 cc (Type: EXPERIMENTAL): Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).